PK

Pandi Karunakaran

Active Director Director DIN 09439795
DIN 09439795 First appointment Dec 2021 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2021
Shareholding value •••• Premium profile

About Pandi Karunakaran

Data last updated:

Pandi Karunakaran is a Director at Procyon Pharmaceuticals Private Limited (since 2021). The company operates in Pharma. Procyon Pharmaceuticals Private Limited reported revenue of ₹5.34 Cr (FY 2025).

DIN 09439795
Primary Designation Director
Industry Pharma
First Appointment 17 Dec 2021
Oldest Company Age 4 yrs
Largest company Procyon Pharmaceuticals Private Limited · ₹5.34 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director17 Dec 20212021₹5.34 Cr (FY 2025)Active

Board colleagues of Pandi Karunakaran

Directorship timeline

Open interactive timeline →
Procyon Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Pandi Karunakaran

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pandi Karunakaran

Pandi Karunakaran currently holds 1 directorship: Procyon Pharmaceuticals Private Limited (Director, since 17 Dec 2021, revenue ₹5.34 Cr (FY 2025)).

Pandi Karunakaran was first appointed on 17 Dec 2021 as Director at Procyon Pharmaceuticals Private Limited.

The current boards of Pandi Karunakaran's companies include Kamaraj (Procyon Pharmaceuticals Private Limited), Udayakumar (Procyon Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available